The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.x

Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

Publications

Hiramatsu K, Ishizuka H, Yamasaki M

Bronchiolar disease associated with gold compounds administration in a patient with rheumatoid arthritis.

Modern rheumatology 2005;15;148-52 — 2005 — 148-52

Schwartzman KJ, Bowie DM, Yeadon C, Fraser R, Sutton ED, Levy RD

Constrictive bronchiolitis obliterans following gold therapy for psoriatic arthritis.

The European respiratory journal 1995 Dec;8;2191-3 — 1995 Dec — 2191-3

Holness L, Tenenbaum J, Cooter NB, Grossman RF

Fatal bronchiolitis obliterans associated with chrysotherapy.

Annals of the rheumatic diseases 1983 Oct;42;593-6 — 1983 Oct — 593-6

Fort JG, Scovern H, Abruzzo JL

Intravenous cyclophosphamide and methylprednisolone for the treatment of bronchiolitis obliterans and interstitial fibrosis associated with crysotherapy.

The Journal of rheumatology 1988;15;850-4 — 1988 — 850-4

O'Duffy JD, Luthra HS, Unni KK, Hyatt RE

Bronchiolitis in a rheumatoid arthritis patient receiving auranofin.

Arthritis and rheumatism 1986 Apr;29;556-9 — 1986 Apr — 556-9